Reading MRK? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MRK free→Reading MRK? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MRK free→NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong. Earnings quality is neutral, and management's track record has been steady. Risk is moderate, and the sector backdrop is a headwind. Compared with sector peers, MRK is typical. Peer multiples imply a price about 75% below where it trades (it looks expensive on this basis); the read is expensive, growth-justified. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 7 valuation methods, at three horizons. Current price $115.23. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $115 MRK trades at 25× p/e — 1.9× the 13× p/e peer median, and above its own 17× history. The market is re-rating it beyond its own range; our $66 fair value is low-confidence here. Analysts: $112–$150. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 75% near-term growth, well above our forecast of about 3%. This describes what's priced in, not a forecast of the move.
Flags: expensive valuation, a turbulent sector regime (Heating).
For similar setups historically (n=2,301): about 43% saw a 20%+ drawdown, and roughly 77% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 2.00x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 50% for the rest of the cohort, n=2269).
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
2 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $2.08 → $-0.15 (-107.4% / 30d). 0 raised, 3 cut, 5 covering analysts.
0 upgrades, 0 downgrades / 30d. 66% of analysts rate Buy.
1 PT revisions / 30d. Avg target 21.5% above current price.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$98.
How much price usually moves either way.
On a bad day, this stock has moved -$250.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $1,137.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
The signal label changed from mixed to mild favorable. Risk remained moderate. The sector backdrop is a headwind. Recent financial performance is strong.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Sales growth below this level could signal weakening demand for key products.
Confirms:Q2 sales growth reported below 5% year over year.
Disproves:Q2 sales growth exceeds 5% year over year.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
Acquisition expands Merck's capabilities in agtech and oncology.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
No upside scenarios in the latest snapshot.
No downside scenarios in the latest snapshot.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Incorporated by reference is a press release issued by Merck & Co., Inc. on April 30, 2026, regarding earnings for the first quarter of 2026, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2. This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Se…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$112.00 – $150.00 (median $141.00) · 4 analysts · as of 2026-06-02
Looks more expensive than peers.
Richer than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Pharmaceuticals.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
MRK Merck & Co. | Typical Show detailsSector percentile: 67 of 100 | expensive | moderate |
LLY Lilly (Eli) | Above typical Show detailsSector percentile: 89 of 100 | expensive | moderate |
JNJ Johnson & Johnson | Above typical Show detailsSector percentile: 75 of 100 | expensive | low |
PFE Pfizer | Typical Show detailsSector percentile: 63 of 100 | full | low |
BMY Bristol Myers Squibb | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on advancing the oncology pipeline with significant regulatory and clinical milestones.
Increase the revenue guidance for the fiscal year 2026.
Raise the expected non-GAAP EPS range for the fiscal year 2026.
Why it matters: KEYTRUDA brings in a lot of money. Its sales trends will affect overall results.
Confirms:KEYTRUDA sales growth remains above 8% year over year.
Disproves:KEYTRUDA sales growth falls below 5% year over year.
Why it matters: Earnings results will show how Merck is doing and what to expect.
Confirms one read:Earnings beat expectations, showing strong growth.
Confirms the other:Earnings did not meet expectations. This may show problems with growth.
Why it matters: Raising EPS guidance shows the business is doing better.
Confirms:Management raises non-GAAP EPS guidance above $5.16 in Q2 2026.
Disproves:Management keeps or lowers non-GAAP EPS guidance below $5.04.
Why it matters: Raising revenue guidance shows stronger sales and growth potential.
Confirms:Management raises revenue guidance in the next earnings call.
Disproves:Revenue guidance remains unchanged or is lowered in the next earnings call.
Why it matters: If this drug is approved, it will grow Merck's blood disease treatments and open new areas.
Confirms:FDA approves TERN-701 before the expected end of the acquisition.
Disproves:FDA denies approval or delays the decision on TERN-701.
Why it matters: New oncology approvals would help Merck's pipeline. This would support revenue growth.
Confirms:Announcement of FDA approval for at least one new oncology treatment in Q2 2026.
Disproves:No new oncology treatments receive FDA approval in Q2 2026.
Why it matters: Good data from these trials could help Merck's cancer treatments and boost future sales.
Confirms:Successful Phase 3 data readouts from at least two oncology trials.
Disproves:Bad Phase 3 data from any cancer trial.
Incorporated by reference is a press release issued by Merck & Co., Inc. on February 3, 2026, regarding earnings for the fourth quarter and year end of 2025, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2. This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabil…
Incorporated by reference is a press release issued by Merck & Co., Inc. on October 30, 2025, regarding earnings for the third quarter of 2025, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2. This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that…
Incorporated by reference is a press release issued by Merck & Co., Inc. on July 29, 2025, regarding earnings for the second quarter of 2025, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2. This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Se…
Costs Associated with Exit or Disposal Activities. On July 25, 2025, the Company approved a new restructuring program (2025 Restructuring Program) designed to position the Company for its next chapter of growth and to successfully advance its pipeline and launch new products across multiple therapeutic areas. As part of this program, the Company expects to eliminate certain positions in sales and administrative organizations, as well as research and development. The Company will, however, con…